Articles by Emily Menendez
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Factors including young age and low preoperative PNI were linked to an unfavorable prognosis in high-risk patients with GIST.
The approval is based on positive results from the phase III RATIONALE-306 study.
The guideline was developed using a multidisciplinary team of oncologists in collaboration with ASCO and the SUO.
Patients with refractory UGI cancers who participated in phase I trials saw benefits in late-line settings.
A new retrospective study has examined the use of 68Ga-DOTATATE PET/CT in all stages of disease.
ctDNA can serve as a major independent prognostic biomarker in patients with stage III colon cancer after surgery.
Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.
Patients with locally advanced GC who achieved pCR after NAC had significantly better survival outcomes.
Encorafenib with cetuximab was approved by the FDA in 2024 for previously treated patients with BRAF V600E-mutant mCRC.
A recent retrospective analysis sought to identify novel actionable alterations in patients with SDH-deficient GISTs.
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Previously presented results of the trial showed favorable PFS rates in the m-FOLFOXIRI and cetuximab arm.
The combination of EVE/LAN can significantly prolong PFS in patients with well-differentiated grade 1/2 GEP-NETs.
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.